Compare CAPR & GLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPR | GLP |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | 4700 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil Refining/Marketing |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 2011 | N/A |
| Metric | CAPR | GLP |
|---|---|---|
| Price | $26.78 | $49.26 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 1 |
| Target Price | $44.63 | ★ $46.00 |
| AVG Volume (30 Days) | ★ 950.2K | 79.2K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 6.40% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $64.13 |
| Revenue Next Year | $3.31 | $11.74 |
| P/E Ratio | ★ N/A | $23.28 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.30 | $39.58 |
| 52 Week High | $40.37 | $56.51 |
| Indicator | CAPR | GLP |
|---|---|---|
| Relative Strength Index (RSI) | 37.76 | 53.87 |
| Support Level | $25.76 | $45.18 |
| Resistance Level | $30.21 | N/A |
| Average True Range (ATR) | 1.25 | 1.67 |
| MACD | -0.15 | -0.08 |
| Stochastic Oscillator | 5.05 | 50.27 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Global Partners LP is a limited partnership that acts as a midstream logistics and marketing company. It is mainly engaged in purchasing, selling, storing and logistics of transporting petroleum and related products. The company owns and operates and control terminal networks of refined petroleum products and renewable fuels in Massachusetts, Maine, Connecticut, Vermont, and other places. It distributes gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, natural gas and propane to wholesalers, retailers and commercial customers. The company operates through three segments i.e. Wholesale, Gasoline Distribution and Station Operations and Commercial. It generates maximum revenue from the GDSO segment.